An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers

Incidence of dose-limiting toxicity (DLTs)

Time frame: Cycle 1 (28 days)

Incidence of adverse events (AEs)

Time frame: From Baseline until study exit (up to approximately 2 years)

Incidence of serious adverse events (SAEs)

Time frame: From Baseline until study exit (up to approximately 2 years)

Incidence of AEs leading to discontinuation

Time frame: From Baseline until study exit (up to approximately 2 years)

Incidence of deaths

Time frame: From Baseline until study exit (up to approximately 2 years)

Incidence of clinically significant changes in clinical laboratory results: Hematology tests

Time frame: From Baseline until disease progression (approximately 2 years)

Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests

Time frame: From Baseline until disease progression (approximately 2 years)

Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests

Time frame: From Baseline until disease progression (approximately 2 years)